March 22, 2022
Video
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
Article
Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
March 21, 2022
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.
Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
March 20, 2022
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.
Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.
Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.
The death rate from cervical cancer has dropped by more than 50% since 1975.
